Withings spent twelve years filing before anyone wrote the cheque
Withings holds 148 patent families: 110 granted and 38 published and pending. Filing began in 2008, with the most recent published filing dated 2025-09-26. The families appear in 8 patent offices: United States, Europe, China, Japan and France.Patent figures from Google Patents Public Data, reviewed 2026-09-17. Funding: $60M Series B, 2020-07-01.
A French health device company raised $60 million in July 2020. The patent record starts in October 2008. Read the file in order and the interesting question is not what the money bought, but what the newest filings are about, and how little they resemble the old ones.
One pulse, eleven years into the record
The Series B lands on 1 July 2020: $60 million, a single line in the record. By then Withings had been filing patents for eleven years and nine months. The first family went in on 13 October 2008. The four years after that produced exactly one family each. A team filing at that pace was not waiting for capital to begin. It had already begun, quietly, and kept going.
The pulse hides what sits on either side of it. Before it, sixty-one families filed between 2008 and 2019. After it, a filing rate that roughly doubled and then stayed there. The funding date is the easiest fact in this story to find and the least useful one. The dates that matter are the ones the company chose for itself, years earlier, with no announcement attached.
One hundred and ten of them survived
Every tick on the arc is one family: 148 in total. The solid amber ones, 110 of them, have been granted. The thin ones, 38, are published and still pending. That is a 74 percent grant share across a file built over seventeen years. Portfolios assembled quickly rarely hold that ratio. Examination removes the speculative claims first, and here most of the claims stayed.
The thin ticks cluster at one end, because pending means recent. Read the arc as a timeline and the pending third is largely the work of the last five years, still moving through offices. The solid section is the decade before the raise. Two different files, really, drawn on the same curve: one already tested, one still being argued.
Examination removes the speculative claims first, and here most of the claims stayed.
The rate changed, then it stayed changed
The bars for 2008 through 2012 are single filings. In 2013 the count jumps to seven and settles: nine, nine, nine, eight, nine across the years to 2018, then six in 2019. That is a steady habit, not a campaign. Then the funding marker, and 2020 comes in at fourteen. 2021 and 2022 both reach twenty. 2023 holds at eighteen. 2024 shows twelve.
The shading at the right edge is the publication lag. Three families are visible for 2025, which tells you almost nothing yet, because filings from the last eighteen months have not surfaced. What the completed bars do say is that the post-2020 rate was not a single burst. Four consecutive years above the entire pre-2020 average, sustained past the point where a raise stops explaining anything.
Who keeps arriving at these documents
Five organisations account for the heaviest citation traffic into this file. Apple Inc cites these filings 132 times. Fitbit Inc, 55. PureWick Corp, 54. Samsung Electronics Co Ltd, 45. Google LLC, 41. Citations are examiner and applicant references, nothing more. They record that when these parties filed, this French file came up.
Look at the shape of that list rather than the names. The top citer alone accounts for more references than the next two combined, and the second tier is not uniform in kind. Different sorts of organisation keep landing on the same 148 families. A file gets cited that often for one reason: it got there first and wrote the claims down.
Eight jurisdictions, chosen one at a time
The boxes are US, EP, CN, JP, FR, CA, AU and ES. Eight offices for a company of this size is a deliberate number. France is home and the first filing date sits there in the record. The US and EP are the expensive pair almost everyone pays for. China and Japan cost real money to prosecute and maintain, and they were paid for anyway.
Canada, Australia and Spain are the ones that tell you something. Nobody files in Spain by reflex. Those boxes are individual decisions, made family by family, about where a claim was worth having. Read together with a 74 percent grant share, this is not a portfolio assembled for a slide. It was assembled for offices where someone expected to need it.
Nobody files in Spain by reflex.
The newest titles do not match the old file
Here is the thing the earlier stages set up. The most recent published filings are a urine analysis device, a second urine analysis device, a cartridge for urine analysis, and a combined mirror and health metric output screen. The most recent of them dates to 26 September 2025. Those are titles from a file that has moved. The velocity did not just increase after 2020. It pointed somewhere new.
The decade of single-digit years built the grants. The four years above eighteen built the pending third. Withings began filing in 2008 and has kept three inventors, Eric Carreel, Thomas Droze and Cédric Hutchings, recurring across the file while 151 names in total have passed through it. Continuity of people, discontinuity of subject. That combination is what the last five years of this record actually shows.
Is the newer file as solid as the older one?
Three things you might already know about this company. None of them settles the question on its own, because each can be explained away by timing, by cost, or by the ordinary lag between filing and grant.
A raise and a legacy file
The 110 grants belong to the decade before 2020, and the post-raise volume is still unexamined. Judgement has to wait for the offices.
The newest titles do not match the old file
Do the 38 pending families concentrate around the urine analysis and cartridge titles, or are they spread across the older subject matter?
Which of the eight offices receive the post-2020 families, and does China and Japan coverage extend to the newest ones?
Do Carreel, Droze and Hutchings appear on the 2024 and 2025 filings, or has the newer work drawn on different names among the 151?
When the shaded 2025 window fills in, does the filing rate hold near the 2021 and 2022 level of twenty?
Following those four would tell you whether the post-2020 filings are a second portfolio being built with intent, or the tail of the first one.
Common questions
How many patents does Withings have?
Withings holds 148 patent families as reviewed in 2026-09: 110 granted and 38 published and pending.
How many of Withings's patents are granted?
110 of the 148 families are granted, or 74 percent. The remaining 38 are published and still under examination.
What technology do Withings's patents cover?
Withings's claims cluster in diagnosis and surgery (A61B), material analysis (G01N) and G01G. Recent filing titles include "Urine analysis device" and "Urine analysis device".
Where has Withings filed patents?
Withings's families appear in 8 patent offices: United States, Europe, China, Japan, France and Canada.
Which companies file patents in the same areas as Withings?
The same CPC groups drew SAMSUNG ELECTRONICS CO LTD, KONINKLIJKE PHILIPS NV, MEDTRONIC INC and BIOSENSE WEBSTER ISRAEL LTD over the last five years. Shared classification indicates a common technology field rather than direct competition.
Who cites Withings's patents?
Patent records from APPLE INC, FITBIT INC, PUREWICK CORP and SAMSUNG ELECTRONICS CO LTD cite Withings's filings. A citation indicates a reference to the work, not evidence of commercial use.
Who invented Withings's patents?
151 inventors are named across the portfolio. The most frequently named is CARREEL ERIC. Inventor names do not establish ownership, which is determined by assignment records.
GET IN TOUCH NOW!
OR SCHEDULE A MEETING
